H1512

Haloperidol

≥98% (TLC), powder, dopamine receptor antagonist

• Synonym(e): 4-[4-(4-Chlorphenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorphenyl)-1-butanon, 4-[4-(4-Chlorphenyl)-4-hydroxypiperidino]-4′-fluorbutyrophenon, 4-[4-(p-Chlorphenyl)-4-hydroxypiperidino]-4′-fluorbutyrophenon
• Empirische Formel (Hill-System): C₂₁H₂₃ClFNO₂
• CAS-Nummer: 52-86-8
• Molekulargewicht: 375.86
• EG-Nummer: 200-155-6
• MDL-Nummer: MFCD00051423
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 24277917
• NACRES: NA.77

Eigenschaften

• product name: Haloperidol, powder
• Form: powder
• Farbe: white
• Löslichkeit: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.39 mg/mL; 0.1 M HCl: 3 mg/mL; DMSO: soluble; H₂O: insoluble; ethanol: soluble
• Ersteller: Johnson & Johnson
• SMILES String: OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3
• InChI: 1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
• InChIKey: LNEPOXFFQSENCJ-UHFFFAOYSA-N
• Angaben zum Gen: human ... ABCB1(5243) , ADRA1A(148) , ADRA2A(150) , ADRA2C(152) , CHRM1(1128) , DRD2(1813) , DRD3(1814) , DRD4(1815) , EBP(10682) , HRH1(3269) , HTR2A(3356) , HTR2C(3358) , HTR7(3363) , KCNH1(3756) , KCNH2(3757) , PRNP(5621) ; rat ... Adra1a(29412) , Adra2a(25083) , Chrm1(25229) , Chrm2(81645) , Drd1a(24316) , Drd2(24318) , Drd3(29238) , Drd4(25432) , Hrh1(24448) , Htr1a(24473) , Htr1b(25075) , Htr2a(29595) , Htr2c(25187) , Oprs1(29336) , Slc6a3(24898) , Slc6a4(25553)

Beschreibung

Anwendung

Haloperidol has been used:

• in ethanol to serves as an inhibitor of Erg2p
• to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines
• in receptor internalization assay
• as an antipsychotic drug in Dulbecco′s Modified Eagle medium

Biochem./physiol. Wirkung

Haloperidol is a butyrophenone antipsychotic. It is also classified as a neuroleptic (powerful tranquilizer). Haloperidol acts as a D2, D3, and D4 dopamine receptor antagonist and thus causes Parkinson′s disorder. It also has a negative effect on the central nervous system.

Leistungsmerkmale und Vorteile

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Piktogramme: GHS06,GHS08
• Signalwort: Danger
• H-Sätze: H301,H315,H317,H319,H335,H361
• P-Sätze: P202 - P261 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338
• Gefahreneinstufungen: Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
• Zielorgane: Respiratory system
• Lagerklassenschlüssel: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable